Modulating neuroinflammation and cognitive function in postoperative cognitive dysfunction via <scp>CCR5</scp>‐<scp>GPCRs</scp>‐Ras‐<scp>MAPK</scp> pathway targeting with microglial <scp>EVs</scp>

Qi Zheng, Junlin Peng, Haitao Wang, Li Wang, Yu Su, Lan Ding, Bin Cao, Yingying Zhao, Qinghe Xing, Jian‐jun YangCNS 2024 · DOI

TL;DR

This study reveals that microglial extracellular vesicles (EVs) carrying the CCR5 receptor can worsen neuroinflammation and cognitive decline in a mouse model of postoperative cognitive dysfunction (POCD). Importantly, by genetically modifying these EVs to lack CCR5, the researchers demonstrated a significant protective effect, suggesting a novel therapeutic strategy for POCD by targeting microglial EVs.

What Problem Does This Paper Address?

Postoperative cognitive dysfunction (POCD) is a common and debilitating condition, particularly in elderly patients, characterized by memory and attention deficits following surgery. While the exact mechanisms are complex, neuroinflammation, driven by activated microglia, is a key contributor. Microglia, the brain's resident immune cells, release inflammatory molecules that can damage neurons and impair cognitive function. The C-C chemokine receptor type 5 (CCR5) has emerged as a significant player in neuroinflammatory processes, often activating signaling pathways like Ras-MAPK, which are implicated in neuronal damage. Extracellular vesicles (EVs), tiny sacs released by cells, are increasingly recognized as crucial mediators of intercellular communication, including in the brain. This paper investigates whether microglial EVs, specifically those expressing CCR5, contribute to POCD and if manipulating CCR5 expression on these EVs can offer a therapeutic benefit.

Methods

The researchers employed a multi-pronged approach to investigate the role of microglial EVs in POCD:

  • In vitro studies: They cultured BV2 microglial cells and stimulated them with LPS to mimic an inflammatory state, generating "activated" EVs (EVs<sup>M1</sup>). They also created EVs from BV2 cells with CCR5 genetically knocked down (EVs<sup>M1-CCR5</sup>). These EVs were then used to treat cultured HT22 neuronal cells to assess their impact on inflammation, proliferation, and apoptosis.
  • EV Characterization: Standard techniques like Transmission Electron Microscopy (TEM) and Nanoparticle Tracking Analysis (NTA) were used to confirm the size and morphology of the isolated EVs. Western blotting was employed to verify the presence of specific EV markers (CD81, CD63) and the upregulation of CCR5 in EVs<sup>M1</sup>.
  • Protein Interaction Analysis: Structure-based docking and Co-immunoprecipitation (Co-IP) were used to investigate the physical interactions between CCR5, G-protein-coupled receptors (GPCRs), and Ras, aiming to elucidate the signaling pathway involved.
  • In vivo POCD Model: A mouse model of POCD was established through surgery. Mice were then treated with either EVs<sup>M1</sup> or EVs<sup>M1-CCR5</sup>.
  • Assessment of Neuroinflammation and Neuronal Health:
    • Immunofluorescence: Staining was used to visualize and quantify markers of microglial activation (Iba1), CCR5 expression, synaptic plasticity (PSD95), and neuronal development (MAP2) in brain tissue.
  • Fluoro-Jade B (FJB) Staining: This technique was used to identify degenerating neurons.
  • Western Blot: Phosphorylation levels of key signaling molecules (p38 and Erk) were assessed to evaluate cellular stress responses.
  • Cognitive Function Assessment: The Morris Water Maze (MWM) test was conducted to evaluate spatial learning and memory in the treated mice.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Microglial EVs are not benign: Activated microglial EVs (EVs<sup>M1</sup>) are not just passive carriers but actively contribute to neuroinflammation and neuronal damage. This challenges a purely passive view of EV function in this context.
  • CCR5 is a critical driver of EV-mediated harm: The presence of CCR5 on microglial EVs appears to be a key factor in their ability to induce neuroinflammation and impair cognitive function. Knocking down CCR5 significantly reverses these detrimental effects.
  • The CCR5-GPCRs-Ras-MAPK pathway is central: The study provides strong evidence for the involvement of this specific signaling cascade in mediating the inflammatory effects of microglial EVs. This pathway represents a potential therapeutic target.
  • Targeted EV modification is feasible and effective: The ability to genetically modify microglial EVs to lack CCR5 and observe protective effects in vivo demonstrates the potential for developing "designer" EVs as therapeutic agents. This opens up exciting possibilities for precision medicine in neurological disorders.
  • EVs can be tracked in vivo: The use of PKH26-labeled EVs and IVIS imaging highlights the potential for using EVs as targeted delivery vehicles within the brain.

Key Results

  • In vitro: EVs<sup>M1</sup> treatment of HT22 cells led to increased apoptosis, decreased proliferation, and elevated inflammatory cytokine release (CCL3, CCL4, CCL5). These effects were reversed by EVs<sup>M1-CCR5</sup>. Phosphorylation of p38 and Erk was also reduced in cells treated with EVs<sup>M1-CCR5</sup>.
  • EV Characterization: EVs<sup>M1</sup> showed significantly higher CCR5 expression compared to control EVs.
  • Protein Interactions: Docking and Co-IP experiments confirmed interactions between CCR5 and GPCR subunits, as well as between GPCRs and Ras, supporting the proposed signaling pathway.
  • In vivo (POCD model):
    • EVs<sup>M1</sup> treatment exacerbated neuroinflammation (increased Iba1, CCR5, p38/Erk phosphorylation) and neuronal degeneration (increased FJB staining) in POCD mice.
  • EVs<sup>M1-CCR5</sup> treatment significantly reduced microglial activation, CCR5 expression, p38/Erk phosphorylation, and neuronal degeneration.
  • Synaptic plasticity markers (PSD95) and neuronal development markers (MAP2) were reduced by POCD and further by EVs<sup>M1</sup>, but restored by EVs<sup>M1-CCR5</sup>.
  • Ultrastructural analysis showed reduced synapse numbers and PSD thickness in POCD and EVs<sup>M1</sup> groups, which were improved by EVs<sup>M1-CCR5</sup>.
  • Cognitive function, as assessed by the Morris Water Maze, was impaired in POCD mice and further worsened by EVs<sup>M1</sup>. EVs<sup>M1-CCR5</sup> treatment significantly improved escape latency and platform crossings, indicating restored memory and learning.

Limitations and Future Work

  • Focus on CCR5: The study primarily focused on CCR5. The authors acknowledge that other chemokine receptors and signaling pathways may also play significant roles in POCD and neuroinflammation, and suggest future research should explore these.
  • In vitro vs. In vivo: While the in vitro results strongly support the findings, the complexity of the in vivo environment always presents challenges in fully replicating cellular interactions.
  • Therapeutic Translation: While promising, the findings are from a mouse model. Further research is needed to translate these findings into human therapies, including optimizing delivery methods and assessing long-term safety and efficacy.
  • Broader Applications: The authors suggest that modulating EV characteristics could be a promising strategy for treating not only POCD but also other neuroinflammatory or neurodegenerative diseases. Future work could explore the applicability of this approach to conditions like Alzheimer's or Parkinson's disease.

Summary updated

Abstract

EVs<sup>M1</sup> induced neuroinflammation via the CCR5-GPCRs-Ras-MAPK pathway, with EVs<sup>M1-CCR5</sup> showing protective effects on POCD progression, suggesting a new therapeutic strategy for POCD management via targeted modification of microglial EVs.
BibTeX
@inproceedings{zheng2024modulating,
  author = {Qi Zheng and Junlin Peng and Haitao Wang and Li Wang and Yu Su and Lan Ding and Bin Cao and Yingying Zhao and Qinghe Xing and Jian‐jun Yang},
  title = {{Modulating neuroinflammation and cognitive function in postoperative cognitive dysfunction via <scp>CCR5</scp>‐<scp>GPCRs</scp>‐Ras‐<scp>MAPK</scp> pathway targeting with microglial <scp>EVs</scp>}},
  booktitle = {CNS},
  year = {2024},
  doi = {10.1111/cns.14924},
}
Figure